A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments DOI Creative Commons
Di Chen, Yuan Xu, Xueping Gao

и другие.

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Апрель 10, 2023

Background: Glioma patients often experience unfavorable outcomes and elevated mortality rates. Our study established a prognostic signature utilizing cuproptosis-associated long non-coding RNAs (CRLs) identified novel biomarkers therapeutic targets for glioma. Methods: The expression profiles related data of glioma were obtained from Cancer Genome Atlas, an accessible online database. We then constructed using CRLs evaluated the prognosis by means Kaplan-Meier survival curves receiver operating characteristic curves. A nomogram based on clinical features was employed to predict individual probability patients. Functional enrichment analysis conducted identify crucial CRL-related enriched biological pathways. role LEF1-AS1 in validated two cell lines (T98 U251). Results: developed model with 9 CRLs. Patients low-risk had considerably longer overall (OS). CRL may serve independently as indicator In addition, functional revealed significant multiple immunological Notable differences observed between risk groups terms immune infiltration, function, checkpoints. further four drugs their different IC50 values groups. Subsequently, we discovered molecular subtypes (cluster one cluster two), subtype exhibiting remarkably OS compared subtype. Finally, that inhibition curbed proliferation, migration, invasion cells. Conclusion: signatures confirmed reliable therapy response Inhibition effectively suppressed growth, gliomas; therefore, presents itself promising biomarker potential target

Язык: Английский

Revisiting the potential of regulated cell death in glioma treatment: a focus on autophagy-dependent cell death, anoikis, ferroptosis, cuproptosis, pyroptosis, immunogenic cell death, and the crosstalk between them DOI Creative Commons

Maowen Luo,

Xingzhao Luan,

Chaoge Yang

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Авг. 9, 2024

Gliomas are primary tumors that originate in the central nervous system. The conventional treatment options for gliomas typically encompass surgical resection and temozolomide (TMZ) chemotherapy. However, despite aggressive interventions, median survival glioma patients is merely about 14.6 months. Consequently, there an urgent necessity to explore innovative therapeutic strategies treating glioma. foundational study of regulated cell death (RCD) can be traced back Karl Vogt's seminal observations cellular demise toads, which were documented 1842. In past decade, Nomenclature Committee on Cell Death (NCCD) has systematically classified delineated various forms mechanisms death, synthesizing morphological, biochemical, functional characteristics. primarily manifests two forms: accidental (ACD), caused by external factors such as physical, chemical, or mechanical disruptions; RCD, a gene-directed intrinsic process coordinates orderly response both physiological pathological cues. Advancements our understanding RCD have shed light manipulation modulation - either through induction suppression potentially groundbreaking approach oncology, holding significant promise. obstacles persist at interface research clinical application, with impediments encountered translating modalities. It increasingly apparent integrative examination molecular underpinnings imperative advancing field, particularly within framework inter-pathway synergy. this review, we provide overview including autophagy-dependent anoikis, ferroptosis, cuproptosis, pyroptosis immunogenic death. We summarize latest advancements regulate interconnections between different processes. By comprehending these connections developing targeted strategies, potential enhance therapy RCD.

Язык: Английский

Процитировано

3

Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance DOI Creative Commons
Liang Shen, Haitao Shen, Tong Wang

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 13, 2025

As a primary brain cancer, glioma presents significant challenges in treatment and prognosis. Identifying reliable biomarkers is crucial for improving patient outcomes. This study focuses on the ABCC3 gene, exploring its function as standalone predictive indictor correlation with immune infiltration resistance to chemotherapy glioma. A multi-faceted approach was adopted this analysis. We scrutinized RNA expression patterns of gene across spectrum cancer types, concentrated focus Our methodological arsenal included bioinformatics analysis, immunohistochemistry (ICH), western blot (WB), cell counting Kit-8 (CCK8) assays. These techniques were instrumental gauging prognostic impact elucidating associations resistance. The investigation revealed elevated levels high grade (HGG) tissues compared lower (LGG) tissues. Notably, upregulation associated shorter overall survival patients Furthermore, emerged an independent factor prognostication, capability 1-, 3-, 5-year rates. far response concerned, ABCC3's correlates positively several cells checkpoint genes. also uncovered role drug resistance, particularly regarding temozolomide (TMZ), therapeutic agent treatment. reveals biomarker glioma, survival, enhanced infiltration, increased chemotherapy. findings emphasize promise novel target therapies.

Язык: Английский

Процитировано

0

Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes DOI Creative Commons

Sishi Tang,

Xinyi Long,

Fangfang Li

и другие.

Hematology, Год журнала: 2025, Номер 30(1)

Опубликована: Фев. 21, 2025

Background Multiple myeloma (MM) is a hematological malignancy with the proliferation of malignant plasma cells. Numerous studies have highlighted critical role ferroptosis in MM. However, how to use ferroptosis-related genes (FRGs) for prognostic prediction and treatment guidance MM remains unknown.

Язык: Английский

Процитировано

0

Genetic Profiles of Ferroptosis in Malignant Brain Tumors and Off-Target Effects of Ferroptosis Induction DOI Creative Commons
Marc Dahlmanns, Eduard Yakubov, Jana Katharina Dahlmanns

и другие.

Frontiers in Oncology, Год журнала: 2021, Номер 11

Опубликована: Дек. 1, 2021

Glioblastoma represents the most devastating form of human brain cancer, associated with a very poor survival rate patients. Unfortunately, treatment options are currently limited and gold standard pharmacological chemotherapeutic drug temozolomide only slightly increases rate. Experimental studies have shown that efficiency can be improved by inducing ferroptosis – recently discovered cell death, which is different from apoptosis, necrosis, or necroptosis and, characterized lipid peroxidation reactive oxygen species accumulation. Ferroptosis also activated to improve malignant stages neuroblastoma, meningioma, glioma. Due their role in cancer treatment, ferroptosis-gene signatures been evaluated for ability predict Despite positive effects during chemotherapy, drugs used induce such as erastin sorafenib well genetic manipulation key players cystine-glutamate exchanger xCT glutathione peroxidase GPx4 impact neuronal function cognitive capabilities. In this review, we give an update on tumors summarize healthy tissues.

Язык: Английский

Процитировано

20

A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments DOI Creative Commons
Di Chen, Yuan Xu, Xueping Gao

и другие.

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Апрель 10, 2023

Background: Glioma patients often experience unfavorable outcomes and elevated mortality rates. Our study established a prognostic signature utilizing cuproptosis-associated long non-coding RNAs (CRLs) identified novel biomarkers therapeutic targets for glioma. Methods: The expression profiles related data of glioma were obtained from Cancer Genome Atlas, an accessible online database. We then constructed using CRLs evaluated the prognosis by means Kaplan-Meier survival curves receiver operating characteristic curves. A nomogram based on clinical features was employed to predict individual probability patients. Functional enrichment analysis conducted identify crucial CRL-related enriched biological pathways. role LEF1-AS1 in validated two cell lines (T98 U251). Results: developed model with 9 CRLs. Patients low-risk had considerably longer overall (OS). CRL may serve independently as indicator In addition, functional revealed significant multiple immunological Notable differences observed between risk groups terms immune infiltration, function, checkpoints. further four drugs their different IC50 values groups. Subsequently, we discovered molecular subtypes (cluster one cluster two), subtype exhibiting remarkably OS compared subtype. Finally, that inhibition curbed proliferation, migration, invasion cells. Conclusion: signatures confirmed reliable therapy response Inhibition effectively suppressed growth, gliomas; therefore, presents itself promising biomarker potential target

Язык: Английский

Процитировано

8